Premium
Amiridine (NIK‐247) and cerebrocrast in the alleviation of cholinergic lesion‐induced learning deficit in male rats
Author(s) -
Männistö Pekka T.,
Kutepova Olga,
Lein Katri,
Lang Aavo,
Soosaar Andres,
Suomela Annika,
Borisenko Sergey A.
Publication year - 1993
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430300404
Subject(s) - antagonist , cholinergic , lesion , pharmacology , psychology , acetylcholinesterase inhibitor , acetylcholinesterase , basal (medicine) , neuroscience , chemistry , medicine , biochemistry , psychiatry , receptor , enzyme , insulin
Learning of the male rats was impaired by injecting ethylcholine aziridinium (AF64A) bilaterally into the basal magnocellular nuclei of Meynert. The performance of the rats in a passive avoidance test and in a one‐way active avoidance test was significantly improved by giving a novel acetylcholinesterase inhibitor, amiridine (NIK‐247; 9‐amino‐2,3,5,6,7,8‐hexahydro‐1H‐cyclopenta(b)‐quinoline monohydrate hydrochloride) after each learning session but not when the drug was given before the sessions. Cerebrocrast, an antagonist of L‐type calcium channels, was not effective in either case. Rather it worsened the learning results when given after the sessions of the active avoidance test. The conclusions in the passive avoidance test were hampered by the observed inconsistent effects of cholinotoxin. © 1993 wiley‐Liss, Inc.